Despite aggressive treatment with conventional therapy, sarcoidosis may be progressive and debilitating. Tumor necrosis factor (TNF)-alpha is critical in the genesis and maintenance of granulomatous inflammation. Agents developed to inhibit TNF-alpha have been approved to treat rheumatoid arthritis and inflammatory bowel disease with unprecedented success. As such, physicians are increasingly using these agents to treat patients with other inflammatory diseases, including sarcoidosis. We report a case of refractory sarcoidosis, involving the lung, eyes, skin, and heart, which flared despite aggressive therapy. Oculocutaneous sarcoid dramatically improved after treatment with the anti-TNF antibody infliximab.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1378/chest.124.5.2028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinico-pathologic correlation in ocular sarcoidosis.
Am J Ophthalmol Case Rep
December 2024
Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Purpose: This case describes the unique course and management of a patient with progressive, refractory multi-system sarcoidosis that initially presented with ocular and dermatologic findings.
Observations: A 47-year-old male presented with acute anterior uveitis and was found to have simultaneous inflammation of his skin at a tattoo site. Diagnosis of ocular sarcoidosis was confirmed through skin biopsy.
Neurosarcoidosis: Current Perspectives on Diagnosis, Management, and Future Directions.
Cureus
September 2024
Internal Medicine, Rawalpindi Medical University, Rawalpindi, PAK.
Article Synopsis
- Neurosarcoidosis is a rare form of sarcoidosis that affects the nervous system, leading to symptoms like seizures, cognitive issues, and cranial nerve problems, which complicate diagnosis and management due to their variability.
- Diagnosing the condition requires a mix of clinical assessments, advanced imaging (like high-resolution MRI and PET scans), and lab tests, but it can be mistaken for conditions like multiple sclerosis.
- Treatment often starts with corticosteroids and may include immunosuppressants or biologic therapies for more severe cases, with ongoing research aimed at better understanding the disease and improving therapies through biomarkers and innovative technologies.
Extrapulmonary sarcoidosis.
J Autoimmun
December 2024
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Article Synopsis
- - Sarcoidosis is a chronic inflammatory disease that arises in genetically susceptible individuals after exposure to certain antigens, primarily affecting the lungs but potentially impacting any organ, including the heart, nervous system, and eyes, which can lead to severe complications.
- - Diagnosis is typically easier when typical symptoms and biopsy findings are present, but it becomes more complex when symptoms manifest in areas outside the lungs without accompanying lung issues.
- - First-line treatment for sarcoidosis involves corticosteroids, while immunosuppressive or biologic medications are used for patients who do not respond to steroids or have refractory disease.
Abatacept and tofacitinib in refractory sarcoidosis: drug survival, safety, and treatment response.
Clin Exp Rheumatol
November 2024
Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Article Synopsis
- The study aimed to evaluate the effectiveness and safety of abatacept and tofacitinib in treating sarcoidosis patients who were unresponsive to previous treatments.
- A total of 41 patients were treated with abatacept, while 12 received tofacitinib, with most tofacitinib patients having prior abatacept treatment.
- After 6 months, both treatments showed high drug survival rates (90% for abatacept, 89% for tofacitinib) and significant responder rates (71% and 67% respectively), indicating they are safe and effective options for patients with persistent symptoms.
Current Practices and Emerging Therapies to Optimize Heart Failure Management in Cardiac Sarcoidosis: A Systematic Review.
Cureus
August 2024
Medicine and Surgery, Jordan University of Science and Technology, Amman, JOR.
Article Synopsis
- * Treatment options for CS include corticosteroids as the primary choice, along with immunosuppressive agents, biological therapies for hard-to-treat cases, and standard heart failure medications to support cardiac function.
- * A systematic review was conducted following PRISMA guidelines, analyzing recent research on heart failure caused by sarcoidosis, narrowing down from 36,755 articles to 11 high-quality studies for evaluation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!